Association of genetic variants with dyslipidemia and chronic kidney disease in a longitudinal population-based genetic epidemiological study

Yoshiji Yamada, Kota Matsui, Ichiro Takeuchi, Tetsuo Fujimaki, Yoshiji Yamada, Kota Matsui, Ichiro Takeuchi, Tetsuo Fujimaki

Abstract

We previously identified 9 genes and chromosomal region 3q28 as susceptibility loci for myocardial infarction, ischemic stroke, or chronic kidney disease (CKD) in Japanese individuals by genome-wide or candidate gene association studies. In the present study, we examined the association of 13 polymorphisms at these 10 loci with the prevalence of hypertriglyceridemia, hyper-low-density lipoprotein (LDL) cholesterolemia, hypo-high-density lipoprotein (HDL) cholesterolemia, or CKD in community-dwelling Japanese individuals. The study subjects comprised 6,027 individuals who were recruited to the Inabe Health and Longevity Study, a longitudinal genetic epidemiological study of atherosclerotic, cardiovascular and metabolic diseases. The subjects were recruited from individuals who visited the Health Care Center at Inabe General Hospital for an annual health checkup, and they were followed up each year (mean follow‑up period, 5 years). Longitudinal analysis with a generalized estimating equation and with adjustment for covariates revealed that rs6929846 of butyrophilin, subfamily 2, member A1 gene (BTN2A1) was significantly associated with the prevalence of hypertriglyceridemia (P=0.0001), hyper-LDL cholesterolemia (P=0.0004), and CKD (P=0.0007); rs2569512 of interleukin enhancer binding factor 3 (ILF3) was associated with hyper-LDL cholesterolemia (P=0.0029); and rs2074379 (P=0.0019) and rs2074388 (P=0.0029) of alpha-kinase 1 (ALPK1) were associated with CKD. Longitudinal analysis with a generalized linear mixed-effect model and with adjustment for covariates among all individuals revealed that rs6929846 of BTN2A1 was significantly associated with the serum concentrations of triglycerides (P=0.0011), LDL cholesterol (P=3.3 x 10(-5)), and creatinine (P=0.0006), as well as with the estimated glomerular filtration rate (eGFR) (P=0.0004); rs2569512 of ILF3 was shown to be associated with the serum concentration of LDL cholesterol (P=0.0221); and rs2074379 (P=0.0302) and rs2074388 (P=0.0336) of ALPK1 were shown to be associated with the serum concentration of creatinine. Similar analysis among individuals not taking any anti‑dyslipidemic medication revealed that rs6929846 of BTN2A1 was significantly associated with the serum concentrations of triglycerides (P=8.3 x 10‑5) and LDL cholesterol (P=0.0004), and that rs2569512 of ILF3 was associated with the serum concentration of LDL cholesterol (P=0.0010). BTN2A1 may thus be a susceptibility gene for hypertriglyceridemia, hyper‑LDL cholesterolemia and CKD in Japanese individuals.

Figures

Figure 1
Figure 1
Longitudinal analysis of the association between the prevalence of (A) hypertriglyceridemia or (B) hyper-low-density lipoprotein (LDL) cholesterolemia and age with a generalized estimating equation, or between the serum concentrations of (C) triglycerides or (D) LDL cholesterol and age with a generalized linear mixed-effect model, according to the genotype for rs6929846 of butyrophilin, subfamily 2, member A1 gene (BTN2A1) (CT + TT vs. CC).
Figure 2
Figure 2
Longitudinal analysis of the association between the prevalence of chronic kidney disease (CKD) and age with (A) a generalized estimating equation, or (B) between the serum concentration of creatinine or (C) estimated glomerular filtration rate (eGFR) and age with a generalized linear mixed-effect model, according to the genotype for rs6929846 of butyrophilin, subfamily 2, member A1 gene (BTN2A1) (CT + TT vs. CC).

References

    1. Heller DA, de Faire U, Pedersen NL, Dahlén G, McClearn GE. Genetic and environmental influences on serum lipid levels in twins. N Engl J Med. 1993;328:1150–1156. doi: 10.1056/NEJM199304223281603.
    1. Ordovas JM. Nutrigenetics, plasma lipids, and cardiovascular risk. J Am Diet Assoc. 2006;106:1074–1081. doi: 10.1016/j.jada.2006.04.016.
    1. Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2014 update: A report from the American Heart Association. Circulation. 2014;129:e28–e292. doi: 10.1161/01.cir.0000441139.02102.80.
    1. Takamatsu N, Abe H, Tominaga T, Nakahara K, Ito Y, Okumoto Y, Kim J, Kitakaze M, Doi T. Risk factors for chronic kidney disease in Japan: A community-based study. BMC Nephrol. 2009;10:34. doi: 10.1186/1471-2369-10-34.
    1. Willer CJ, Schmidt EM, Sengupta S, et al. Global Lipids Genetics Consortium: Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274–1283. doi: 10.1038/ng.2797.
    1. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707–713. doi: 10.1038/nature09270.
    1. Aulchenko YS, Ripatti S, Lindqvist I, et al. ENGAGE Consortium: Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet. 2009;41:47–55. doi: 10.1038/ng.269.
    1. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41:56–65. doi: 10.1038/ng.291.
    1. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189–197. doi: 10.1038/ng.75.
    1. Yamada Y, Matsuo H, Warita S, et al. Prediction of genetic risk for dyslipidemia. Genomics. 2007;90:551–558. doi: 10.1016/j.ygeno.2007.08.001.
    1. Yamada Y, Kato K, Hibino T, et al. Prediction of genetic risk for metabolic syndrome. Atherosclerosis. 2007;191:298–304. doi: 10.1016/j.atherosclerosis.2006.05.035.
    1. Yamada Y, Ichihara S, Kato K, et al. Genetic risk for metabolic syndrome: Examination of candidate gene polymorphisms related to lipid metabolism in Japanese people. J Med Genet. 2008;45:22–28. doi: 10.1136/jmg.2007.052415.
    1. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010;375:1296–1309. doi: 10.1016/S0140-6736(09)62004-3.
    1. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315. doi: 10.1097/01.ASN.0000123691.46138.E2.
    1. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT, Chronic Kidney, Disease Prognosis. Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet. 2010;375:2073–2081. doi: 10.1016/S0140-6736(10)60674-5.
    1. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1–S266.
    1. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M, Koyama A. Risk factors for chronic kidney disease in a community-based population: A 10-year follow-up study. Kidney Int. 2007;71:159–166. doi: 10.1038/sj.ki.5002017.
    1. Friedman DJ, Pollak MR. Genetics of kidney failure and the evolving story of APOL1. J Clin Invest. 2011;121:3367–3374. doi: 10.1172/JCI46263.
    1. Köttgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet. 2009;41:712–717. doi: 10.1038/ng.377.
    1. Chambers JC, Zhang W, Lord GM, et al. Genetic loci influencing kidney function and chronic kidney disease. Nat Genet. 2010;42:373–375. doi: 10.1038/ng.566.
    1. Köttgen A, Pattaro C, Böger CA, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet. 2010;42:376–384. doi: 10.1038/ng.568.
    1. Böger CA, Gorski M, Li M, et al. CKDGen Consortium: Association of eGFR-related loci identified by GWAS with incident CKD and ESRD. PLoS Genet. 2011;7:e1002292. doi: 10.1371/journal.pgen.1002292.
    1. Pattaro C, Köttgen A, Teumer A, et al. CARDIoGRAM Consortium; ICBP Consortium; CARe Consortium; Wellcome Trust Case Control Consortium 2 (WTCCC2): Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet. 2012;8:e1002584. doi: 10.1371/journal.pgen.1002584.
    1. Kao WH, Klag MJ, Meoni LA, et al. Family Investigation of Nephropathy and Diabetes Research Group: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008;40:1185–1192. doi: 10.1038/ng.232.
    1. Liu CT, Garnaas MK, Tin A, et al. CKDGen Consortium: Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. PLoS Genet. 2011;7:e1002264. doi: 10.1371/journal.pgen.1002264.
    1. Okada Y, Sim X, Go MJ, et al. KidneyGen Consortium; CKDGen Consortium; GUGC consortium: Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nat Genet. 2012;44:904–909. doi: 10.1038/ng.2352.
    1. Yamada Y, Nishida T, Ichihara S, et al. Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations. Atherosclerosis. 2011;215:145–152. doi: 10.1016/j.atherosclerosis.2010.12.005.
    1. Yamada Y, Fuku N, Tanaka M, et al. Identification of CELSR1 as a susceptibility gene for ischemic stroke in Japanese individuals by a genome-wide association study. Atherosclerosis. 2009;207:144–149. doi: 10.1016/j.atherosclerosis.2009.03.038.
    1. Yamada Y, Nishida T, Ichihara S, et al. Identification of chromosome 3q28 and ALPK1 as susceptibility loci for chronic kidney disease in Japanese individuals by a genome-wide association study. J Med Genet. 2013;50:410–418. doi: 10.1136/jmedgenet-2013-101518.
    1. Yamada Y, Matsuo H, Segawa T, et al. Assessment of genetic risk for myocardial infarction. Thromb Haemost. 2006;96:220–227.
    1. Fujimaki T, Kato K, Yoshida T, et al. Association of genetic variants with myocardial infarction in Japanese individuals with chronic kidney disease. Thromb Haemost. 2009;101:963–968.
    1. Oguri M, Kato K, Yokoi K, et al. Association of genetic variants with myocardial infarction in Japanese individuals with metabolic syndrome. Atherosclerosis. 2009;206:486–493. doi: 10.1016/j.atherosclerosis.2009.02.037.
    1. Yamada Y, Matsui K, Takeuchi I, Oguri M, Fujimaki T. Association of genetic variants with hypertension in a longitudinal population-based genetic epidemiological study. Int J Mol Med. 2015;35:1189–1198.
    1. Shimokata S, Oguri M, Fujimaki T, Horibe H, Kato K, Yamada Y. Association between polymorphisms of the α-kinase 1 gene and type 2 diabetes mellitus in community-dwelling individuals. Biomed Rep. 2013;1:940–944.
    1. Ueyama C, Horibe H, Fujimaki T, Oguri M, Kato K, Yamada Y. Association of genetic variants of CELSR1 and 3q28 with hypertension in community-dwelling individuals. Biomed Rep. 2013;1:840–844.
    1. Oguri M, Fujimaki T, Horibe H, Kato K, Ichihara S, Yamada Y. Association of a polymorphism of BTN2A1 with chronic kidney disease in community-dwelling individuals. Biomed Rep. 2013;1:868–872.
    1. Fujimaki T, Horibe H, Oguri M, Kato K, Yamada Y. Association of genetic variants of the α-kinase 1 gene with myocardial infarction in community-dwelling individuals. Biomed Rep. 2014;2:127–131.
    1. Horibe H, Ueyama C, Fujimaki T, Oguri M, Kato K, Ichihara S, Yamada Y. Association of a polymorphism of BTN2A1 with dyslipidemia in community-dwelling individuals. Mol Med Rep. 2014;9:808–812.
    1. Murakata Y, Fujimaki T, Yamada Y. Association of a butyrophilin, subfamily 2, member A1 gene polymorphism with hypertension. Biomed Rep. 2014;2:818–822.
    1. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–992. doi: 10.1053/j.ajkd.2008.12.034.
    1. Itoh Y, Mizuki N, Shimada T, Azuma F, Itakura M, Kashiwase K, Kikkawa E, Kulski JK, Satake M, Inoko H. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics. 2005;57:717–729. doi: 10.1007/s00251-005-0048-3.
    1. Gibbons RD, Hedeker D, DuToit S. Advances in analysis of longitudinal data. Annu Rev Clin Psychol. 2010;6:79–107. doi: 10.1146/annurev.clinpsy.032408.153550.
    1. Cheng J, Edwards LJ, Maldonado-Molina MM, Komro KA, Muller KE. Real longitudinal data analysis for real people: Building a good enough mixed model. Stat Med. 2010;29:504–520.
    1. Fujimaki T, Kato K, Oguri M, et al. Association of a polymorphism of BTN2A1 with dyslipidemia in East Asian populations. Exp Ther Med. 2011;2:745–749.
    1. Yoshida T, Kato K, Horibe H, Oguri M, Fukuda M, Satoh K, Aoyagi Y, Shinkai S, Nozawa Y, Yamada Y. Association of a genetic variant of BTN2A1 with chronic kidney disease in Japanese individuals. Nephrology (Carlton) 2011;16:642–648.
    1. Arnett HA, Escobar SS, Viney JL. Regulation of costimulation in the era of butyrophilins. Cytokine. 2009;46:370–375. doi: 10.1016/j.cyto.2009.03.009.
    1. Oguri M, Kato K, Yoshida T, et al. Association of a genetic variant of BTN2A1 with metabolic syndrome in East Asian populations. J Med Genet. 2011;48:787–792. doi: 10.1136/jmg.2010.088138.
    1. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J Lipid Res. 2004;45:1169–1196. doi: 10.1194/jlr.R300019-JLR200.
    1. Esteve E, Ricart W, Fernández-Real JM. Dyslipidemia and inflammation: An evolutionary conserved mechanism. Clin Nutr. 2005;24:16–31. doi: 10.1016/j.clnu.2004.08.004.
    1. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009;119:1135–1145. doi: 10.1161/CIRCULATIONAHA.108.810721.
    1. Reiss AB. Effects of inflammation on cholesterol metabolism: Impact on systemic lupus erythematosus. Curr Rheumatol Rep. 2009;11:255–260. doi: 10.1007/s11926-009-0036-y.
    1. Kawakami T, Mimura I, Shoji K, Tanaka T, Nangaku M. Hypoxia and fibrosis in chronic kidney disease: Crossing at pericytes. Kidney Int Suppl. 2011;2014;4:107–112. doi: 10.1038/kisup.2014.20.
    1. Schnaper HW, Kopp JB. Why kidneys fail: Report from an American Society of Nephrology Advances in Research Conference. J Am Soc Nephrol. 2006;17:1777–1781. doi: 10.1681/ASN.2006030267.
    1. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest. 2008;118:3522–3530. doi: 10.1172/JCI36150.
    1. Brosius FC., III New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord. 2008;9:245–254. doi: 10.1007/s11154-008-9100-6.
    1. Shim J, Lim H, R Yates J, Karin M. Nuclear export of NF90 is required for interleukin-2 mRNA stabilization. Mol Cell. 2002;10:1331–1344. doi: 10.1016/S1097-2765(02)00730-X.
    1. Hu Q, Lu YY, Noh H, Hong S, Dong Z, Ding HF, Su SB, Huang S. Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression. Oncogene. 2013;32:3933–3943. doi: 10.1038/onc.2012.414.
    1. Wang SJ, Tu HP, Ko AM, Chiang SL, Chiou SJ, Lee SS, Tsai YS, Lee CP, Ko YC. Lymphocyte α-kinase is a gout-susceptible gene involved in monosodium urate monohydrate-induced inflammatory responses. J Mol Med (Berl) 2011;89:1241–1251. doi: 10.1007/s00109-011-0796-5.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir